Clinical-stage biotechnology firm Imunon Inc. (NASDAQ: IMNN ) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients.
The company reported site activation and patient enrollment speeds that significantly outpace original forecasts and standard industry benchmarks .
Enrollment Rates Exceed Industry Benchmarks
The trial progressed from protocol submission to site activation in roughly six months. It reached its first randomized patient within two months of approval—one-third of the standard industry benchmark.
Clinical Timeline And Interim Regulatory Goals
Imunon now projects full enrollment completion by the second quarter of 2029.
High conversion rates from pre-screening to randomization, backed by promising overall survival data from the Phase 2 OVATION 2 study, have fueled participant interest.
Furthermore, two pre-planned interim analyses are scheduled to potentially enable an early Biologics License Application submission for full regulatory approval if specific targets are reached.
Strong Safety Profile Confirmed
IMNN-001 has maintained a favorable safety and tolerability profile throughout the trial .
Researchers observed no instances of cytokine release syndrome, systemic toxicities, or serious immune-related adverse events. Safety outcomes remain comparable between the treatment arm (IMNN-001 with neoadjuvant and adjuvant chemotherapy) and the control arm, consistent with findings from an ongoing Phase 2 Minimal Residual Disease study.
Recent Independent Data Monitoring Committee reviews noted no safety concerns across ongoing studies.
IMNN Stock Price Activity: Imunon shares were up 1.95% at $1.57 during premarket trading Thursday, according to Benzinga Pro data .
Photo by Aunt Spray via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: News General Biotech Health Care Exclusives Market-Moving Exclusives